You have read all your free articles, to continue reading subscribe to read the rest of this content.
We asked the CEO of Herantis Pharma, Pekka Simula, about what is in their pipeline right now, about their strategy to reach market and about patient-driven innovation. Herantis Pharma was created by a merger of two pharma companies, Hermo Pharma and Laurantis Pharma. It has a broad product portfoAlready a…
Elicera Therapeutics has announced that it has completed its first share issue and secured SEK 13.2 million in financing. The company is based on research by professor Magnus Essand’s research group at Uppsala University and will focus on CAR T-cells and oncolytic viruses. “In the CAR T-ceAlready a subscriber Login…
Business development in a clinical stage vaccine company is constantly changing, intellectually challenging and meaningful job that pushes developments in society. Caspar Foghsgaard is Director of Business Development at the Norwegian vaccine platform company Vaccibody. The company mainly focusesAlready a subscriber Login You have read all your free articles, to…
Abera Bioscience has found the right recipe for giving its innovative and versatile vaccine platform the best possible conditions to succeed. Uppsala-based Abera Bioscience was founded ten years ago, as a spin-out from the biosimilars company Xbrane Bioscience. Maria Alriksson, CEO of Abera and fAlready a subscriber Login You have…
